Business Context and Reporting Period
This Form 6-K filing by I-MAB (also referenced as Novabridge Biosciences in metadata) covers the month of August 2024, specifically dated August 7, 2024. The report details a significant corporate governance change regarding the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report focused on auditor changes rather than financial performance results.
Material Changes
- Auditor Dismissal: The Audit Committee approved the dismissal of PricewaterhouseCoopers Zhong Tian LLP ("PwC China") effective August 7, 2024.
- Auditor Appointment: PricewaterhouseCoopers LLP ("PwC US") was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Historical Audit Status: Reports by PwC China for fiscal years 2022 and 2023 contained no adverse opinions, disclaimers, or qualifications.
Management Commentary and Risks
Management confirmed that during the fiscal years ended December 31, 2023 and 2022, and the subsequent period through August 7, 2024, there were no disagreements with PwC China regarding accounting principles, practices, financial statement disclosures, or auditing scope. Additionally, no reportable events occurred during this timeframe. The company also stated that no consultations were held with PwC US regarding accounting principles or audit opinions prior to their appointment.
Investor Verification Checklist
- Verify the effective date of the auditor transition (August 7, 2024).
- Review the attached letter from the predecessor auditor (Exhibit 99.2) to confirm their agreement with the disclosures.
- Confirm the absence of any undisclosed disagreements or reportable events with the former auditor.
- Note that this filing does not contain updated financial performance data; refer to the most recent Form 20-F for financial metrics.